4.78
4.78 (0%)
As of Feb 14, 2025
Galecto, Inc. [GLTO]
Source:
Company Overview
Galecto, Inc. is a clinical-stage biotechnology company developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and liver diseases.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | 45-70-70-52-10 |
| Industry | manufacturing |
| CEO | Hans T. Schambye |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-22.3 |
| Net Income | $-21.4 |
| Net Cash | $-7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -77.5% |
| Profit as % of Stockholder Equity | -135.4% |
Management Effectiveness
| Return on Equity | -135.4% |
| Return on Assets | -125.1% |
| Turnover Ratio | |
| EBITA | $-22.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $17.1 |
| Total Liabilities | $1.3 |
| Operating Cash Flow | $-18.6 |
| Investing Cash Flow | $11.7 |
| Financing Cash Flow | $0 |
